Severe asthma remaining well‐controlled after mepolizumab discontinuation: A case report and literature review

Severe asthma remaining well‐controlled after mepolizumab discontinuation: A case report and literature review

Abstract Mepolizumab, a humanized anti‐IL‐5 monoclonal antibody used for severe asthma, results in a reduced rate of asthma exacerbation, improved lung function, reduced oral corticosteroid use, and improved quality of life. A 62‐year‐old man using high‐dose inhaled corticosteroid visited our hospit...

Full description

Bibliographic Details
Main Authors: Takahiro Matsuyama, Yuya Tomioka, Hiromi Matsuyama, Yusuke Kamenohara, Kengo Tanigawa, Yoichi Dotake, Yoko Hagihara, Koichi Takagi, Kentaro Machida, Hiromasa Inoue
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:Respirology Case Reports
Subjects:
asthma control
eosinophil
mepolizumab
severe asthma
Online Access:https://doi.org/10.1002/rcr2.1158

Internet

https://doi.org/10.1002/rcr2.1158

Similar Items